Fi3 FINANCIAL ADVISORS LLC Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Fi3 FINANCIAL ADVISORS LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 13.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,728 shares of the company’s stock after selling 435 shares during the period. Fi3 FINANCIAL ADVISORS LLC’s holdings in Johnson & Johnson were worth $394,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Virtu Financial LLC grew its position in shares of Johnson & Johnson by 1,962.6% during the fourth quarter. Virtu Financial LLC now owns 60,104 shares of the company’s stock valued at $8,692,000 after purchasing an additional 57,190 shares in the last quarter. Quantbot Technologies LP purchased a new position in Johnson & Johnson during the 4th quarter valued at approximately $6,314,000. Beddow Capital Management Inc. grew its holdings in Johnson & Johnson by 1.4% during the 4th quarter. Beddow Capital Management Inc. now owns 52,555 shares of the company’s stock valued at $7,601,000 after buying an additional 725 shares in the last quarter. ZEGA Investments LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at approximately $945,000. Finally, Millstone Evans Group LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $1,449,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $163.40 on Friday. The stock has a market cap of $393.76 billion, a price-to-earnings ratio of 24.57, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a 50-day moving average of $156.99 and a two-hundred day moving average of $156.33.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.29 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on JNJ. Bank of America raised their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Raymond James dropped their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.